Streetwise Articles By Production Types

Co. Uses RNA Editing as Treatment for Rare Disease

Research Report

Andrew Fein (10/03/2022)

The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report

Dr. Elemer Piros (09/30/2022)

Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial

Streetwise Reports (09/30/2022)

Shares of oncology-focused biopharmaceutical company Immuneering Corp. traded 9% higher after the firm reported it received U.S. FDA clearance for its IND Application for a Phase 1/2a clinical trial of IMM-1-104 for use in treatment of advanced solid tumors with RAS mutations. The company expects to enroll the first patient in the study in Q4/22.

Tags: Biotechnology / Pharmaceuticals

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial

Streetwise Reports (09/29/2022)

Shares of Eisai Co. Ltd. traded 58% higher yesterday after the company reported topline data from its global Phase 3 clinical study demonstrating that its lecanemab significantly met the primary and key secondary endpoints in reducing mild cognitive impairment due to Alzheimer's disease.

Tags: Biotechnology / Pharmaceuticals

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report

Edward White (09/29/2022)

The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Oncology Co.'s Shares Erupt on Signing Global License Deal

Streetwise Reports (09/27/2022)

Shares of clinical-stage immuno-oncology company LAVA Therapeutics NV traded nearly 100% higher yesterday after the firm reported that it has entered into a global licensing agreement with Seagen Inc. to advance its LAVA-1223, a preclinical gamma delta bispecific T cell engager designed for use in the treatment of EGFR-expressing solid tumors.

Tags: Biotechnology / Pharmaceuticals

Opportunity for Investors Found in Psychedelics Space

Research Report

Patrick R. Trucchio (09/27/2022)

Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.

Tags: Psychedelics

US Biotech Firm Keeps Growing Revenue

Research Report

Scott Henry (09/26/2022)

Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report.

Tags: TechnologyHealthcare Services

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report

Dr. Joseph Pantginis (09/23/2022)

To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report

Dr. David Nierengarten (09/23/2022)

Argenx SE has "several upcoming catalysts," noted a Wedbush report.

Tags: Special SituationsBiotechnology / Pharmaceuticals

FDA Approves Hearing Loss Drug for Child Chemo Patients

Streetwise Reports (09/21/2022)

Shares of Fennec Pharmaceuticals Inc. traded 14% higher after the company reported it received approval from the U.S. FDA for its PEDMARK® (sodium thiosulfate injection) for use in reducing the risk of ototoxicity in pediatric patients who are undergoing or completed chemotherapy for non-metastatic solid tumors.

Tags: Biotechnology / Pharmaceuticals

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World

Streetwise Reports (09/21/2022)

The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.

Tags: Life Sciences Tools & DiagnosticsTechnologyHealthcare Services

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report

Dr. David Nierengarten (09/20/2022)

The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Dermatology Co.'s Target Price Much Higher Than Current

Research Report

Dr. Jonathan Aschoff (09/20/2022)

The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data

Streetwise Reports (09/20/2022)

Satsuma Pharmaceuticals Inc. shares traded 12% higher to a new 52-week high after the company reported positive results from its Phase 3 long-term study of STS101 for use in acute treatment of migraine attacks. The company expects to receive further efficacy data from its Phase 3 SUMMIT trial in Q4/22, which it believes will support submission of an NDA with the U.S. FDA in Q1/23.

Tags: Biotechnology / Pharmaceuticals

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report

Dr. Yi Chen (09/17/2022)

The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

FDA Grants Approval for Drug Improving Kidney Function

Streetwise Reports (09/16/2022)

Shares of Mallinckrodt Plc. traded 28% higher yesterday after the company reported that the U.S. FDA has issued approval for its Terlivaz® (terlipressin) for injection for use in treating hepatorenal syndrome, a serious and life-threatening condition that is accompanied by rapid reduction in kidney function.

Tags: Biotechnology / Pharmaceuticals

Price Target on US Biopharma Co. Boosted by $15

Research Report

Julian Harrison (09/15/2022)

The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

New Drug Shown To Help Patients With Desmoid Tumors

Research Report

Dr. David Nierengarten (09/15/2022)

This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Several Trials of Co.'s Fluid Pump To Read Out This Year

Research Report

Dr. Yi Chen (09/14/2022)

Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report.

Tags: Medical Devices

Co. Advancing Drug Class With Broad Potential

Research Report

Dr. Thomas Shrader (09/13/2022)

This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion

Clive Maund (09/13/2022)

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Target Six Times Current Price

Research Report

Francois Brisebois (09/13/2022)

One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price.

Tags: Psychedelics

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

Streetwise Reports (09/12/2022)

One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Tags: PsychedelicsBiotechnology / Pharmaceuticals

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report

Dr. Jonathan Aschoff (09/12/2022)

Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

The Life Sciences Report

The Latest Articles from Streetwise Reports

Co. Uses RNA Editing as Treatment for Rare Disease

Interim Results From Phase 2b Trial Are 'Encouraging'

Biopharma Co. Awarded FDA Clearance for Advanced Solid Tumors Trial

Pharma Co. Meets Primary Endpoint in Phase 3 Alzheimer's Trial

Biopharma Asks for Emergent Use in US of New COVID Drug

Oncology Co.'s Shares Erupt on Signing Global License Deal

Opportunity for Investors Found in Psychedelics Space

US Biotech Firm Keeps Growing Revenue

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Analyst Says Buy Before Biotech Co.'s Clinical Trials

FDA Approves Hearing Loss Drug for Child Chemo Patients

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World

Important Catalyst Expected Soon for Cancer Drug Co.

Dermatology Co.'s Target Price Much Higher Than Current

Biopharma Co.'s Shares Rise on Phase 3 Migraine Trial Data

Second Trial of New Eczema Drug To Commence in Q4/22

FDA Grants Approval for Drug Improving Kidney Function

Price Target on US Biopharma Co. Boosted by $15

New Drug Shown To Help Patients With Desmoid Tumors

Several Trials of Co.'s Fluid Pump To Read Out This Year

Co. Advancing Drug Class With Broad Potential

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Biotech Co.'s Target Six Times Current Price

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

More Experts